The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Neuroprotection in Parkinson Disease: Mysteries, Myths, and Misconceptions
Abstract
Parkinson disease is an age-related neurodegenerative disease that affects approximately 1 million persons in the United States. Current therapies provide effective control of symptoms, particularly in the early stages of the disease, but most patients develop motor complications with long-term treatment, and features develop such as postural instability, falling, and dementia that are not adequately controlled with existing medications. Accordingly, neuroprotective therapy that might slow, stop, or reverse disease progression is urgently needed. While many agents appear to be promising based on laboratory studies, selecting clinical end points for clinical trials that are not confounded by symptomatic effects of the study intervention has been difficult. More recently, neuroimaging end points have been used as biomarkers of disease progression, but again there are concerns that they may be influenced by regulatory effects of the drugs used. We review clinical trials aimed at detecting neuroprotection in Parkinson disease and address the controversies surrounding the interpretation of these studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rascol, O., Brooks, D. J., Korczyn, A. D., De Deyn, P. P., Clarke, C. E., & Lang, A. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005183422004 · Cited by 1,539
Effects of Tocopherol and Deprenyl on the Progression of Disability in Early Parkinson's Disease
(1993) · New England Journal of Medicine · doi:10.1056/nejm199301213280305 · Cited by 1,221
Effects of Coenzyme Q10 in Early Parkinson Disease: Evidence of Slowing of the Functional Decline
Shults, C. W. (2002) · Archives of Neurology · doi:10.1001/archneur.59.10.1541 · Cited by 984
Parkinson Disease in Twins: An Etiologic Study
Tanner, C. M., Ottman, R., Goldman, S. M., Ellenberg, J., Chan, P., Mayeux, R., & Langston, J. W. (1999) · JAMA · doi:10.1001/jama.281.4.341 · Cited by 867
Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL‐PET study
Whone, A. L., Watts, R. L., Stoessl, A. J., Davis, M., Reske, S., Nahmias, C., Lang, A. E., Rascol, O., Ribeiro, M. J., Remy, P., et al. (2003) · Annals of Neurology · doi:10.1002/ana.10609 · Cited by 829
Pramipexole vs Levodopa as initial treatment for Parkinson disease: A randomized controlled trial
Holloway, R. G., Shoulson, I., Kieburtz, K. D., McDermott, M., Tariot, P. N., Kamp, C., Day, D., Shinaman, A., Fahn, S., Lang, A. E., et al. (2000) · JAMA · Cited by 798
A radical hypothesis for neurodegeneration
Olanow, C. W. (1993) · Trends in Neurosciences · doi:10.1016/0166-2236(93)90070-3 · Cited by 722
Self-citationAn algorithm (decision tree) for the management of Parkinson’s disease (2001): Treatment Guidelines
Olanow, C. W., Watts, R. L., & Koller, W. C. (2001) · Neurology · doi:10.1212/wnl.56.suppl_5.s1 · Cited by 715
Self-citationA Controlled Trial of Rasagiline in Early Parkinson Disease: The TEMPO Study
(2002) · Archives of Neurology · doi:10.1001/archneur.59.12.1937 · Cited by 579
Morrish, P. K., Rakshi, J. S., Bailey, D. L., Sawle, G. V., & Brooks, D. J. (1998) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.64.3.314 · Cited by 510
Genetic and environmental factors in the cause of Parkinson's disease
Warner, T. T., & Schapira, A. H. V. (2003) · Annals of Neurology · doi:10.1002/ana.10487 · Cited by 399
Self-citationApoptosis in Parkinson's disease: Signals for neuronal degradation
Tatton, W. G., Chalmers-Redman, R., Brown, D., & Tatton, N. (2003) · Annals of Neurology · doi:10.1002/ana.10489 · Cited by 397
[ 123 I]β-CIT SPECT imaging assessment of the rate of Parkinson’s disease progression
Marek, K., Innis, R., van Dyck, C., Fussell, B., Early, M., Eberly, S., Oakes, D., & Seibyl, J. (2001) · Neurology · doi:10.1212/wnl.57.11.2089 · Cited by 347
Snow, B. J., Tooyama, I., McGeer, E. G., Yamada, T., Calne, D. B., Takahashi, H., & Kimura, H. (1993) · Annals of Neurology · doi:10.1002/ana.410340304 · Cited by 336
Murer, M. G., Dziewczapolski, G., Menalled, L. B., García, M. C., Agid, Y., Gershanik, O., & Raisman‐Vozari, R. (1998) · Annals of Neurology · doi:10.1002/ana.410430504 · Cited by 232
Meiergerd, S. M., Patterson, T. A., & Schenk, J. O. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb02185.x · Cited by 224
Pirker, W., Djamshidian, S., Asenbaum, S., Gerschlager, W., Tribl, G., Hoffmann, M., & Brücke, T. (2002) · Movement Disorders · doi:10.1002/mds.1265 · Cited by 213
Proteolytic stress: A unifying concept for the etiopathogenesis of Parkinson’s disease
McNaught, K. S. P., & Olanow, C. W. (2003) · Annals of Neurology · doi:10.1002/ana.10512 · Cited by 203
Self-citationManagement of Parkinson's disease: An evidence-based review
Lang, A. E., & Lees, A. (2002) · Movement Disorders · doi:10.1002/mds.5554 · Cited by 184
Dopamine transporter messenger RNA in Parkinson's disease and control substantia nigra neurons
Uhl, G. R., Walther, D. M., Mash, D. C., Faucheux, B. A., & Javoy-Agid, F. (1994) · Annals of Neurology · doi:10.1002/ana.410350421 · Cited by 179
Slowing Parkinson’s disease progression: Recent dopamine agonist trials
Ahlskog, J. E. (2003) · Neurology · doi:10.1212/01.wnl.0000044047.58984.2f · Cited by 161
D 2 -Like Dopamine Autoreceptor Activation Reduces Quantal Size in PC12 Cells
Pothos, E. N., Przedborski, S., Davila, V., Schmitz, Y., & Sulzer, D. (1998) · Journal of Neuroscience · doi:10.1523/jneurosci.18-15-05575.1998 · Cited by 153
Influence of l -dopa and pramipexole on striatal dopamine transporter in early PD
Guttman, M., Stewart, D. E., Hussey, D., Wilson, A., Houle, S., & Kish, S. J. (2001) · Neurology · doi:10.1212/wnl.56.11.1559 · Cited by 151
Dopamine agonists and neuroprotection in parkinson's disease
Olanow, C. W., Jenner, P. G., & Brooks, D. J. (1998) · Annals of Neurology · doi:10.1002/ana.410440725 · Cited by 131
Self-citationInnis, R. B., MAREK, K. L., Sheff, K., Zoghbi, S. S., CASTRONUOVO, J. J., Feigin, A., & Seibyl, J. P. (1999) · Movement Disorders · doi:10.1002/1531-8257(199905)14:3<436::aid-mds1008>3.0.co;2-j · Cited by 130
Aromatic L‐Amino Acid Decarboxylase Activity of Mouse Striatum Is Modulated via Dopamine Receptors
Hadjiconstantinou, M., Wemlinger, T. A., Sylvia, C.-H., Hubble, J. P., & Neff, N. H. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb03503.x · Cited by 118
Joyce, J. N., Smutzer, G., Whitty, C. J., Myers, A., & Bannon, M. J. (1997) · Movement Disorders · doi:10.1002/mds.870120609 · Cited by 113
Slowing the progression of Alzheimer disease: methodologic issues.
Leber, P. D. (1997) · PubMed · Cited by 104
Neuroprotection and dopamine agonists
Schapira, A. H. V. (2002) · Neurology · doi:10.1212/wnl.58.suppl_1.s9 · Cited by 102
Self-citationAre Dopamine Receptor Agonists Neuroprotective in Parkinson??s Disease?
Le, W., & Jankovic, J. J. (2001) · Drugs & Aging · doi:10.2165/00002512-200118060-00001 · Cited by 100
Protein Kinase A Activity May Kinetically Upregulate the Striatal Transporter for Dopamine
Batchelor, M., & Schenk, J. O. (1998) · Journal of Neuroscience · doi:10.1523/jneurosci.18-24-10304.1998 · Cited by 97
Gordon, I., Weizman, R., & Rehavi, M. (1996) · European Journal of Pharmacology · doi:10.1016/0014-2999(95)00770-9 · Cited by 92
Kreiss, D. S., Bergstrom, D. A., González, A. M., Huang, K., Sibley, D. R., & Walters, J. R. (1995) · European Journal of Pharmacology · doi:10.1016/0014-2999(95)00069-w · Cited by 87
Differential effects of levodopa on dopaminergic function in early and advanced Parkinson's disease
Torstenson, R., Hartvig, P., Långström, B., Westerberg, G., & Tedroff, J. (1997) · Annals of Neurology · doi:10.1002/ana.410410308 · Cited by 86
Zhu, M., Juorio, A. V., Paterson, I. A., & Boulton, A. A. (1993) · European Journal of Pharmacology · doi:10.1016/0014-2999(93)90843-7 · Cited by 79
Activation of phosphoinositide 3-kinase by D2 receptor prevents apoptosis in dopaminergic cell lines
Nair, V. D., Olanow, C. W., & Sealfon, S. C. (2003) · Biochemical Journal · doi:10.1042/bj20030017 · Cited by 78
Self-citationNeuroprotection for Parkinson's disease: Prospects and promises
Olanow, C. W., Schapira, A. H. V., & Agid, Y. (2003) · Annals of Neurology · doi:10.1002/ana.10566 · Cited by 75
Self-citationNurmi, E., Bergman, J., Eskola, O., Solin, O. H., Hinkka‐Yli‐Salomäki, S., Sonninen, P. H., & Rinne, J. O. (2000) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-200011000-00010 · Cited by 71
Initial agonist treatment of Parkinson disease
Albin, R. L., & Frey, K. A. (2003) · Neurology · doi:10.1212/01.wnl.0000052681.28286.52 · Cited by 70
Dopamine autoreceptor function is lost in advanced Parkinson’s disease
Ekesbo, A., Rydin, E., Torstenson, R., Sydow, O., Låengström, B., & Tedroff, J. (1999) · Neurology · doi:10.1212/wnl.52.1.120 · Cited by 68
Unaltered [3H]GBR-12935 binding after chronic treatment with dopamine active drugs
Allard, P. O., Eriksson, K., Ross, S. B., & Marcusson, J. O. (1990) · Psychopharmacology · doi:10.1007/bf02244092 · Cited by 57
In Vivo Regulation of DOPA Decarboxylase by Dopamine Receptors in Rat Brain
Cumming, P. D., Ase, A. R., Laliberté, C. L., Kuwabara, H., & GJEDDE, A. H. (1997) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-199711000-00014 · Cited by 51
Modulation of [3H]mazindol binding sites in rat striatum by dopaminergic agents
Ikawa, K., Watanabe, A., Kaneno, S., & Toru, M. (1993) · European Journal of Pharmacology · doi:10.1016/0014-2999(93)90390-4 · Cited by 51
Rationale for the use of dopamine agonists as neuroprotective agents in Parkinson's disease
Schapira, A. H. V., & Olanow, C. W. (2003) · Annals of Neurology · doi:10.1002/ana.10514 · Cited by 49
Self-citationLevodopa: why the controversy?
Agid, Y., Olanow, C. W., & Mizuno, Y. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09733-7 · Cited by 42
Self-citationWooten, G. F. (2003) · Neurology · doi:10.1212/wnl.60.3.360 · Cited by 42
Cited by
Samii, A., Nutt, J. G., & Ransom, B. R. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16305-8 · Cited by 1,265
The scientific and clinical basis for the treatment of Parkinson disease (2009)
Olanow, C. W., Stern, M. B., & Sethi, K. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a1d44c · Cited by 908
Self-citationA Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease
Olanow, C. W., Rascol, O., Hauser, R., Feigin, P. D., Jankovic, J., Lang, A., Langston, W., Melamed, E., Poewe, W., Stocchi, F., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809335 · Cited by 901
Self-citationMicroglial activation and dopamine terminal loss in early Parkinson's disease
Ouchi, Y., Yoshikawa, E., Sekine, Y., Futatsubashi, M., Kanno, T., Ogusu, T., & Torizuka, T. (2005) · Annals of Neurology · doi:10.1002/ana.20338 · Cited by 843
Parkinson disease: from pathology to molecular disease mechanisms
Dexter, D. T., & Jenner, P. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.01.018 · Cited by 707
Metadata
- Authors
- Schapira, A. H. V., & Olanow, C. W.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2004-01-21
- Volume
- 291
- Issue
- 3
- Pages
- 358
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2062781235
- Cited by
- 288
- References
- 46
- FWCI
- 16.45
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.